ObvioHealth and SPRIM PRO Launch Integrated Digital Patient Monitoring Solution for High-Risk Therapies
核心洞察
ObvioHealth (搜索) and SPRIM PRO (搜索) launched an integrated digital patient monitoring and clinical support offering for therapies requiring enhanced clinical oversight, including REMS programs.
A 2026 peer-reviewed analysis found that 57% of novel therapies approved by the FDA between 2000 and 2024 were specialty medicines.
The offering combines ObvioHealth (搜索)'s ObvioGo (搜索) digital health platform with SPRIM PRO (搜索)'s more than 25 years of clinical research and remote monitoring expertise.
ObvioHealth (搜索) and SPRIM PRO (搜索) announced on Sept. 10, 2026, the launch of their Integrated Digital Patient Monitoring and Clinical Support Solution for High-Risk Therapies, a strategic business offering that combines digital health technology, clinical operations and patient support services into a single solution for pharmaceutical and biotechnology sponsors.
The launch responds to a structural shift in pharmaceutical pipelines toward specialty medicines, biologics, cell and gene therapies and other high-risk treatments that require clinical oversight beyond the point of care. According to a 2026 peer-reviewed analysis of FDA approvals from 2000 to 2024, 57% of novel therapies approved during that period were specialty medicines. The companies noted that specialty medicines have accounted for more than half of all novel FDA drug approvals since 2012.
Scope of the Offering
The solution is designed for pharmaceutical and biotechnology companies developing or commercializing therapies that require enhanced patient monitoring. It supports Risk Evaluation and Mitigation Strategy (REMS) programs, broader patient support initiatives, specialty therapeutics, infusion therapies, advanced biologics, cell and gene therapies and other high-touch treatment pathways where ongoing clinical oversight is essential.
The offering integrates ObvioHealth (搜索)'s ObvioGo (搜索) digital health platform with SPRIM PRO (搜索)'s more than 25 years of clinical research, patient support and remote patient monitoring experience. Rather than coordinating multiple technology vendors and service providers, sponsors can work with a single partner to design, deploy and manage patient monitoring programs from clinical development through commercialization.
ObvioGo (搜索) is purpose-built for clinical research and patient monitoring and enables digital engagement, electronic clinical outcome assessments (eCOA), eConsent, telehealth, remote data collection and configurable workflows across decentralized, hybrid and site-based programs.
Remote Monitoring and Post-Administration Observation
For therapies requiring extended post-administration observation, sponsors may incorporate technology-enabled remote monitoring as part of a hybrid patient monitoring strategy when clinically appropriate and aligned with the study protocol or product labeling. The offering includes digital symptom reporting, telehealth interactions, configurable escalation pathways and real-time clinical oversight intended to maintain visibility into patient safety while providing flexibility for patients, healthcare providers and care teams. SPRIM PRO (搜索) procures, stores and ships products direct to patients.
The solution is designed to support organizations from late-stage clinical development through commercialization and post-market patient support, with the flexibility to tailor monitoring workflows to each therapy's requirements.
Executive Perspectives
"Technology alone doesn't transform patient monitoring—it must be paired with clinical expertise and thoughtful patient engagement," said Ivan Jarry, Chief Executive Officer of ObvioHealth (搜索). "By combining ObvioHealth's digital platform with SPRIM PRO (搜索)'s deep clinical experience, we're helping pharmaceutical companies build patient monitoring programs that are scalable, patient-centered, and designed to support the evolving needs of today's most advanced therapies."
"As therapeutic regimens become increasingly complex, sponsors need flexible monitoring solutions that extend beyond traditional models of care," said Dr. Susan Dallabrida, Chief Executive Officer of SPRIM PRO (搜索). "For more than 25 years, SPRIM PRO has partnered with global healthcare organizations to design and execute complex remote patient monitoring and patient support programs. We are very excited about our partnership with ObvioHealth (搜索) because we are delivering an integrated solution that combines technology, clinical expertise, and decentralized operational excellence to help sponsors navigate the next generation of patient monitoring with certainty."
SPRIM PRO (搜索) is a global CRO and patient healthcare organization with more than 25 years of experience supporting pharmaceutical, biotechnology, medical device and consumer health organizations, providing clinical operations, remote clinical care, telehealth, logistics support, storage and shipping, and digital training. ObvioHealth (搜索) is a digital health technology company advancing decentralized clinical research and remote patient monitoring through its configurable ObvioGo (搜索) platform.